Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

2.27
-0.05 (-2.16%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :20,311
Date :05-01-2025

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

4月 28th, 2025|Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical已关闭评论

Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two [...]

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

2月 11th, 2025|Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin已关闭评论

New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public [...]

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt

10月 7th, 2024|Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt已关闭评论

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for [...]

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock

6月 26th, 2024|Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock已关闭评论

NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board [...]